,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
[]
dr. obha presents the herb trial, t-dxd in biliary tract cancer. 36.4% orr. #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.